COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT IN TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN SWEDEN

被引：0
|
作者：
Clements, K. M. [1 ]
Hulbert, E. M. [2 ]
Panchmatia, H. R. [1 ]
Eriksson, M. [3 ]
Wittrup-Jensen, K. U. [4 ]
Nilsson, J. [5 ]
Weinstein, M. C. [6 ]
机构：
[1] OptumInsight, Cambridge, MA USA
[2] OptumInsight, Eden Prairie, MN USA
[3] Bayer AB, Solna, Sweden
[4] Bayer Pharma AG, Berlin, Germany
[5] OptumInsight, Stockholm, Sweden
[6] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.1168
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A506 / A506
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT INJECTION (IAI) IN TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE US
    Vitti, R.
    Clements, K. M.
    Panchmatia, H.
    Hulbert, E.
    Wittrup-Jensen, K.
    Lewis, B. E.
    VALUE IN HEALTH, 2013, 16 (03) : A177 - A177
  • [2] COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN GREECE
    Kourlaba, G.
    Tzanetakos, C.
    Datseris, J.
    Rouvas, A.
    Arzoumanidou, D.
    Maniadakis, N.
    VALUE IN HEALTH, 2015, 18 (07) : A421 - A421
  • [3] THE COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT (IVT-AFL) IN TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN AN ITALIAN SETTING
    D'Ausilio, A.
    Midena, E.
    Pilotto, E.
    Calligari, N.
    Bianchi, C.
    Wittrup-Jensen, K. U.
    VALUE IN HEALTH, 2013, 16 (07) : A505 - A505
  • [4] Intravitreal aflibercept for neovascular age-related macular degeneration
    Xu, David
    Kaiser, Peter K.
    IMMUNOTHERAPY, 2013, 5 (02) : 121 - 130
  • [5] Aflibercept for Intravitreal Injection In Neovascular Age-Related Macular Degeneration
    Frampton, James E.
    DRUGS & AGING, 2012, 29 (10) : 839 - 846
  • [6] Aflibercept for Intravitreal InjectionIn Neovascular Age-Related Macular Degeneration
    James E. Frampton
    Drugs & Aging, 2012, 29 : 839 - 846
  • [7] Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
    Yu, Justin S.
    Carlton, Rashad
    Agashivala, Neetu
    Hassan, Tarek
    Wykoff, Charles C.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (06): : 743 - 752
  • [8] Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
    Hurley S.F.
    Matthews J.P.
    Guymer R.H.
    Cost Effectiveness and Resource Allocation, 6 (1)
  • [9] Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis
    Hernandez, Luis
    Lanitis, Tereza
    Cele, Clifford
    Toro-Diaz, Hector
    Gibson, Andrea
    Kuznik, Andreas
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (07): : 608 - 616
  • [10] Cost-effectiveness of intravitreal therapy in Age-Related Macular Degeneration
    Neri, Piergiorgio
    Arapi, Ilir
    Eandi, Chiara Maria
    Pirani, Vittorio
    Mariotti, Cesare
    Giovannini, Alfonso
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2014, 15 (04) : 129 - 138
12345